ALT NASDAQ
Altimmune, Inc.
1W: +0.3%
1M: -15.6%
3M: -33.1%
YTD: -37.5%
1Y: -36.7%
3Y: -29.2%
5Y: -77.3%
$2.90
-0.03 (-1.02%)
Weekly Expected Move ±12.0%
$2
$3
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$255.9M
52W Range2.56-7.73
Volume1,988,383
Avg Volume3,944,761
Beta0.17
Dividend—
Analyst Ratings
Company Info
CEOJerome Benedict Durso
Employees59
SectorHealthcare
IndustryBiotechnology
IPO Date2017-05-26
Websitealtimmune.com
910 Clopper Road
Gaithersburg, MD 20878
US
Gaithersburg, MD 20878
US
240 654 1450
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lawver Teri L | A-Award | 48,800 | $2.82 | 2026-05-01 |
| Sohn Catherine A. | A-Award | 48,800 | $2.82 | 2026-05-01 |
| Jorkasky Diane | A-Award | 48,800 | $2.82 | 2026-05-01 |
| Schafer Klaus | A-Award | 48,800 | $2.82 | 2026-05-01 |
| Pisano Wayne | A-Award | 48,800 | $2.82 | 2026-05-01 |